Research Coverage

Redeye Coverage

Neola Medical is covered by Redeye, an independent equity research and investment banking firm focused on Nordic growth companies. Their analyses provide investors with valuable insights into our business, strategy, and market potential. Redeye publishes updates on Neola Medical on a regular basis, and the reports are available to both current shareholders and potential investors. You can access the initiation of coverage report and latest research updates through the links below.

Initiation of Coverage Report

Latest research updates at Redeye

Please note: Access to additional information at Redeye requires a free Redeye membership.

Presentations

Catch up on Neola Medical’s latest highlights, including investor presentations and interviews at Redeye.

Redeye Interview Q2 2025 with CEO Hanna Sjöström

In a new interview with Redeye’s Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2). Watch the full interview here: Redeye...

WATCH NOW

Did you miss Neola Medical’s Q2 2025 report presentation?

Catch up on Neola Medical’s Q2 2025 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study. CEO Hanna Sjöström shares insights into these key...

WATCH NOW

CEO Hanna Sjöström on Clinical and Strategic Milestones – Redeye Interview Q1 2025

Following a strengthened shareholder base and the first baby enrolled in Neola Medical’s Swedish clinical pilot study, CEO Hanna Sjöström joins Redeye to discuss recent milestones and what lies ahead. She shares insights into the company’s clinical progress, recent...

WATCH NOW

Redeye Interview: Neola Medical Strengthens Ownership Base with Institutional Investors

In an interview with Redeye, CEO Hanna Sjöström, discusses the company’s latest capital raise of approximately SEK 20 million and its significance for the future. For the first time, the company has attracted institutional investors, Cicero Funds and Adrigo Funds,...

WATCH NOW

Redeye Interview Q4 2024 with CEO Hanna Sjöström

Following the release of Neola Medical’s Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company’s progress toward the clinical phase, and the upcoming first clinical study on preterm born babies...

WATCH NOW

Did you miss Neola Medical’s Q4 2024 report presentation?

Catch up on key insights into Neola Medical’s latest developments as we prepare for clinical studies and continue strengthening our presence in the U.S. market. CEO Hanna Sjöström provides an update on key milestones and strategic progress in the U.S. and looks ahead...

WATCH NOW

Highlights from Neola Medical’s Presentation at Redeye Technology & Life Science Day

Earlier this week, Neola Medical participated in the Redeye Technology and Life Science Day in Stockholm, showcasing the company’s significant progress and outlining its future plans during an engaging presentation and dynamic Q&A session. Discover deeper insights...

WATCH NOW

Neola Medical’s presentation at Stora Aktiedagarna in Stockholm

Yesterday CEO Hanna Sjöström showcased Neola Medical’s vision and strategic advancements during the presentation at Stora Aktiedagarna in Stockholm, highlighting the future of neonatal care. The presentation was met with great interest, filling the room with engaged...

WATCH NOW

Neola Medical: Key Milestones & Future Plans at Redeye Medtech & Diagnostics Event 2024

Did you miss CEO Hanna Sjöström's investor presentation at the Redeye Theme: Medtech & Diagnostics Event 2024? Don’t worry—you can still catch up on all the exciting updates! In her presentation, CEO Hanna Sjöström highlighted Neola Medical’s significant progress...

WATCH NOW

The Q3 report presentation of 2024!

Watch when CEO Hanna Sjöström and CFO David Folkesson presented Neola Medical’s Q3-report of 2024. Learn more about the company’s financial position and the progress from this quarter, toward market approval in the U.S. After the presentation a brief Q&A follows....

WATCH NOW

Stay updated on our progress and milestones

Neola Medical is currently in clinical phase with Neola®, undergoing our first clinical study on preterm born babies in Sweden. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.